Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT01925274

Public ClinicalTrials.gov record NCT01925274. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A RANDOMIZED PHASE 2 STUDY OF PF-05212384 PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN IN PATIENTS WITH KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of cetuximab plus Irinotecan. A Japanese Lead in Cohort will assess the safety of the combination of PF-05212384 + irinotecan in patients enrolled at Japanese sites.

Study identification

NCT ID
NCT01925274
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
19 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 14, 2013
Primary completion
Apr 5, 2016
Completion
Apr 5, 2016
Last update posted
Jan 7, 2019

2013 – 2016

United States locations

U.S. sites
25
U.S. states
5
U.S. cities
13
Facility City State ZIP Site status
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center Bakersfield California 93309
Drug Management Only: UCLA West Medical Pharmacy, Att: Steven L Wong, Pharm D Los Angeles California 90095-7349
Drug Management Only: UCLA West Medical Pharmacy Los Angeles California 90095-7349
UCLA West Medical Pharmacy Los Angeles California 90095-7349
Regulatory Management Only: TRIO-US Central Administration Los Angeles California 90095
TRIO-US Central Administration (Regulatory Management only) Los Angeles California 90095
TRIO_US Los Angeles California 90095
West Valley Hematology/Oncology Med Group Northridge California 91328
Siteman Cancer Center - St Peters City of Saint Peters Missouri 63376
Siteman Cancer Center - West County Creve Coeur Missouri 63141
Barnes-Jewish Hospital St Louis Missouri 63110
Washington University School of Medicine St Louis Missouri 63110
Siteman Cancer Center - South County St Louis Missouri 63129
Regulatory Office: Comprehensive Cancer Centers of Nevada Henderson Nevada 89014
Comprehensive Cancer Centers of Nevada Henderson Nevada 89052
Comprehensive Cancer Centers of Nevada Henderson Nevada 89074
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89128
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89148
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
Roswell Park Cancer Institute Buffalo New York 14263
Kadlec Clinic Hematology and Oncology Kennewick Washington 99336
Kadlec Medical Center Richland Washington 99352
Outpatient Imaging Center Richland Washington 99352
Medical Oncology Associates, PS Spokane Washington 99208
Spokane Valley Cancer Center Spokane Valley Washington 99216

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01925274, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 7, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01925274 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →